{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T21:17:25Z","timestamp":1769116645378,"version":"3.49.0"},"reference-count":205,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2016,10,1]],"date-time":"2016-10-01T00:00:00Z","timestamp":1475280000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"funder":[{"DOI":"10.13039\/501100001659","name":"Deutsche Forschungsgemeinschaft","doi-asserted-by":"publisher","award":["DFG HE 2073\/5-1"],"award-info":[{"award-number":["DFG HE 2073\/5-1"]}],"id":[{"id":"10.13039\/501100001659","id-type":"DOI","asserted-by":"publisher"}]},{"name":"BIOSS Centre for Biological Signalling Studies"},{"name":"European Section of the Aldosterone Council"},{"DOI":"10.13039\/501100009944","name":"F\u00f6rderkreis Dresdener Herz-Kreislauf-Tage","doi-asserted-by":"crossref","id":[{"id":"10.13039\/501100009944","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Pharmacology & Therapeutics"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1016\/j.pharmthera.2016.07.004","type":"journal-article","created":{"date-parts":[[2016,7,26]],"date-time":"2016-07-26T13:22:44Z","timestamp":1469539364000},"page":"136-149","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Pharmacology of heart failure: From basic science to novel therapies"],"prefix":"10.1016","volume":"166","author":[{"given":"Achim","family":"Lother","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Lutz","family":"Hein","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.pharmthera.2016.07.004_bb0005","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1093\/eurjhf\/hfq017","article-title":"Interleukin-1beta modulation using a genetically engineered antibody prevents adverse cardiac remodelling following acute myocardial infarction in the mouse","volume":"12","author":"Abbate","year":"2010","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0010","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1016\/j.amjcard.2014.11.003","article-title":"Comparative safety of interleukin-1 blockade with anakinra in patients with ST-segment elevation acute myocardial infarction (from the VCU-ART and VCU-ART2 pilot studies)","volume":"115","author":"Abbate","year":"2015","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0015","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1016\/j.stem.2014.10.003","article-title":"In vivo activation of a conserved microRNA program induces mammalian heart regeneration","volume":"15","author":"Aguirre","year":"2014","journal-title":"Cell Stem Cell"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0020","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1161\/HYPERTENSIONAHA.110.157271","article-title":"Aldosterone synthase inhibition with LCI699: A proof-of-concept study in patients with primary aldosteronism","volume":"56","author":"Amar","year":"2010","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0025","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1038\/nrm3611","article-title":"Diversifying microRNA sequence and function","volume":"14","author":"Ameres","year":"2013","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0030","doi-asserted-by":"crossref","first-page":"569","DOI":"10.1016\/j.cell.2013.07.013","article-title":"BET bromodomains mediate transcriptional pause release in heart failure","volume":"154","author":"Anand","year":"2013","journal-title":"Cell"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0035","doi-asserted-by":"crossref","first-page":"28930","DOI":"10.1074\/jbc.M303113200","article-title":"Dose-dependent blockade to cardiomyocyte hypertrophy by histone deacetylase inhibitors","volume":"278","author":"Antos","year":"2003","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0040","doi-asserted-by":"crossref","first-page":"1853","DOI":"10.1172\/JCI27438","article-title":"CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy","volume":"116","author":"Backs","year":"2006","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0045","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1073\/pnas.0813013106","article-title":"The delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload","volume":"106","author":"Backs","year":"2009","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0050","doi-asserted-by":"crossref","first-page":"884","DOI":"10.1001\/jama.2015.10081","article-title":"Effect of finerenone on albuminuria in patients with diabetic nephropathy: A randomized clinical trial","volume":"314","author":"Bakris","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0055","doi-asserted-by":"crossref","first-page":"2136","DOI":"10.1172\/JCI70577","article-title":"Cardiac fibroblast-derived microRNA passenger strand-enriched exosomes mediate cardiomyocyte hypertrophy","volume":"124","author":"Bang","year":"2014","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0060","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1002\/cmdc.201200081","article-title":"Discovery of BAY 94-8862: A nonsteroidal antagonist of the mineralocorticoid receptor for the treatment of cardiorenal diseases","volume":"7","author":"Barfacker","year":"2012","journal-title":"ChemMedChem"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0065","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1016\/j.pharmthera.2005.01.005","article-title":"Physiology and pharmacology of the cardiac pacemaker (\u201cfunny\u201d) current","volume":"107","author":"Baruscotti","year":"2005","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0070","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1038\/415198a","article-title":"Cardiac excitation-contraction coupling","volume":"415","author":"Bers","year":"2002","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0075","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1111\/j.1476-5381.1996.tb15505.x","article-title":"Mode of action of bradycardic agent, S 16257, on ionic currents of rabbit sinoatrial node cells","volume":"118","author":"Bois","year":"1996","journal-title":"Br J Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0080","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1161\/CIRCHEARTFAILURE.114.001915","article-title":"Effects of sildenafil on ventricular and vascular function in heart failure with preserved ejection fraction","volume":"8","author":"Borlaug","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0085","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1056\/NEJMra0800239","article-title":"Biomarkers in heart failure","volume":"358","author":"Braunwald","year":"2008","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0090","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1016\/j.jacc.2015.01.033","article-title":"The path to an angiotensin receptor antagonist-neprilysin inhibitor in the treatment of heart failure","volume":"65","author":"Braunwald","year":"2015","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0095","doi-asserted-by":"crossref","first-page":"966","DOI":"10.1016\/j.jacc.2011.03.054","article-title":"S100A1 genetically targeted therapy reverses dysfunction of human failing cardiomyocytes","volume":"58","author":"Brinks","year":"2011","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0100","doi-asserted-by":"crossref","first-page":"e56280","DOI":"10.1371\/journal.pone.0056280","article-title":"miR-21 promotes fibrogenic epithelial-to-mesenchymal transition of epicardial mesothelial cells involving Programmed Cell Death 4 and Sprouty-1","volume":"8","author":"Bronnum","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0105","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1146\/annurev-med-052914-091923","article-title":"New pharmacological strategies to increase cGMP","volume":"67","author":"Buglioni","year":"2016","journal-title":"Annu Rev Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0110","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1161\/CIRCULATIONAHA.113.001878","article-title":"Pathological ventricular remodeling: Mechanisms: Part 1 of 2","volume":"128","author":"Burchfield","year":"2013","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0115","doi-asserted-by":"crossref","first-page":"2772","DOI":"10.1172\/JCI36154","article-title":"MicroRNA-208a is a regulator of cardiac hypertrophy and conduction in mice","volume":"119","author":"Callis","year":"2009","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0120","doi-asserted-by":"crossref","first-page":"4123","DOI":"10.1073\/pnas.1015081108","article-title":"Histone deacetylase (HDAC) inhibitors attenuate cardiac hypertrophy by suppressing autophagy","volume":"108","author":"Cao","year":"2011","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0125","doi-asserted-by":"crossref","first-page":"1163","DOI":"10.3892\/mmr.2013.1622","article-title":"Pravastatin slows the progression of heart failure by inhibiting the c-Jun N-terminal kinase-mediated intrinsic apoptotic signaling pathway","volume":"8","author":"Cao","year":"2013","journal-title":"Mol Med Rep"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0130","doi-asserted-by":"crossref","first-page":"3133","DOI":"10.1161\/01.CIR.0000077913.60364.D2","volume":"107","author":"Chung","year":"2003","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0135","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/S0140-6736(98)11181-9","article-title":"The Cardiac Insufficiency Bisoprolol Study II (CIBIS-II): A randomised trial","volume":"353","author":"CIBIS-II","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0140","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1016\/S0140-6736(11)61126-4","article-title":"The effects of the cardiac myosin activator, omecamtiv mecarbil, on cardiac function in systolic heart failure: A double-blind, placebo-controlled, crossover, dose-ranging phase 2 trial","volume":"378","author":"Cleland","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0145","first-page":"1429","article-title":"Effects of enalapril on mortality in severe congestive heart failure. Results of the Cooperative North Scandinavian Enalapril Survival Study (CONSENSUS). The CONSENSUS Trial Study Group","volume":"316","author":"CONSENSUS","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0150","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1093\/eurjhf\/hfs060","article-title":"Heart rate achieved or beta-blocker dose in patients with chronic heart failure: Which is the better target?","volume":"14","author":"Cullington","year":"2012","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0155","doi-asserted-by":"crossref","first-page":"e0118664","DOI":"10.1371\/journal.pone.0118664","article-title":"The emperor's new clothes: PDE5 and the heart","volume":"10","author":"Degen","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0160","doi-asserted-by":"crossref","first-page":"23407","DOI":"10.1074\/jbc.M112.363812","article-title":"Raf kinase inhibitor protein (RKIP) dimer formation controls its target switch from Raf1 to G protein-coupled receptor kinase (GRK) 2","volume":"287","author":"Deiss","year":"2012","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0165","doi-asserted-by":"crossref","first-page":"1424","DOI":"10.1161\/hc3601.095574","article-title":"Improvement in survival and cardiac metabolism after gene transfer of sarcoplasmic reticulum Ca(2+)-ATPase in a rat model of heart failure","volume":"104","author":"del Monte","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0170","doi-asserted-by":"crossref","first-page":"904","DOI":"10.1161\/hc0802.105564","article-title":"Targeting phospholamban by gene transfer in human heart failure","volume":"105","author":"del Monte","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0175","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/ng.1068","article-title":"Epigenetic repression of cardiac progenitor gene expression by Ezh2 is required for postnatal cardiac homeostasis","volume":"44","author":"Delgado-Olguin","year":"2012","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0180","doi-asserted-by":"crossref","first-page":"967","DOI":"10.1093\/eurheartj\/ehi190","article-title":"Long-term prognostic value of resting heart rate in patients with suspected or proven coronary artery disease","volume":"26","author":"Diaz","year":"2005","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0185","doi-asserted-by":"crossref","first-page":"2469","DOI":"10.1161\/01.CIR.0000165128.39715.87","article-title":"Functional role of phosphodiesterase 3 in cardiomyocyte apoptosis: Implication in heart failure","volume":"111","author":"Ding","year":"2005","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0190","doi-asserted-by":"crossref","first-page":"776","DOI":"10.1038\/ng.3324","article-title":"Trbp regulates heart function through microRNA-mediated Sox6 repression","volume":"47","author":"Ding","year":"2015","journal-title":"Nat Genet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0195","doi-asserted-by":"crossref","first-page":"1282","DOI":"10.1038\/ncb2866","article-title":"Nfat and miR-25 cooperate to reactivate the transcription factor Hand2 in heart failure","volume":"15","author":"Dirkx","year":"2013","journal-title":"Nat Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0200","first-page":"565","article-title":"microRNA-21 promotes cardiac fibrosis and development of heart failure with preserved left ventricular ejection fraction by up-regulating Bcl-2","volume":"7","author":"Dong","year":"2014","journal-title":"Int J Clin Exp Pathol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0205","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1007\/s11897-016-0290-z","article-title":"Soluble guanylate cyclase stimulators: A novel treatment option for heart failure associated with cardiorenal syndromes?","volume":"13","author":"Dubin","year":"2016","journal-title":"Curr Heart Fail Rep."},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0210","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1161\/01.RES.62.2.191","article-title":"Atrial stretch, not pressure, is the principal determinant controlling the acute release of atrial natriuretic factor","volume":"62","author":"Edwards","year":"1988","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0215","doi-asserted-by":"crossref","first-page":"958","DOI":"10.1161\/CIRCRESAHA.113.302187","article-title":"Sarcoplasmic reticulum Ca-ATPase and heart failure 20 years later","volume":"113","author":"Eisner","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0220","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/j.immuni.2013.11.019","article-title":"Embryonic and adult-derived resident cardiac macrophages are maintained through distinct mechanisms at steady state and during inflammation","volume":"40","author":"Epelman","year":"2014","journal-title":"Immunity"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0225","doi-asserted-by":"crossref","first-page":"57","DOI":"10.1093\/eurheartj\/ehs196","article-title":"Cinaciguat, a soluble guanylate cyclase activator, unloads the heart but also causes hypotension in acute decompensated heart failure","volume":"34","author":"Erdmann","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0230","doi-asserted-by":"crossref","first-page":"29932","DOI":"10.1074\/jbc.M110.131342","article-title":"A new mode of mineralocorticoid receptor antagonism by a potent and selective nonsteroidal molecule","volume":"285","author":"Fagart","year":"2010","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0235","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/nrd4360","article-title":"Histone deacetylases and their inhibitors in cancer, neurological diseases and immune disorders","volume":"13","author":"Falkenberg","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0240","doi-asserted-by":"crossref","first-page":"F1462","DOI":"10.1152\/ajprenal.00285.2010","article-title":"Mineralocorticoid receptor degradation is promoted by Hsp90 inhibition and the ubiquitin-protein ligase CHIP","volume":"299","author":"Faresse","year":"2010","journal-title":"Am J Physiol Ren Physiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0245","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1016\/j.jchf.2016.02.016","article-title":"Neprilysin inhibition in the time of precision medicine","volume":"4","author":"Feldman","year":"2016","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0250","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nrd4286","article-title":"Targeting bromodomains: Epigenetic readers of lysine acetylation","volume":"13","author":"Filippakopoulos","year":"2014","journal-title":"Nat Rev Drug Discov"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0255","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1093\/eurheartj\/ehw132","article-title":"A randomized controlled study of finerenone vs. eplerenone in patients with worsening chronic heart failure and diabetes mellitus and\/or chronic kidney disease","volume":"37","author":"Filippatos","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0260","doi-asserted-by":"crossref","first-page":"196","DOI":"10.1016\/S0140-6736(02)09455-2","article-title":"Efficacy and safety of intravenous levosimendan compared with dobutamine in severe low-output heart failure (the LIDO study): A randomised double-blind trial","volume":"360","author":"Follath","year":"2002","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0265","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(08)61170-8","article-title":"Ivabradine for patients with stable coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0270","doi-asserted-by":"crossref","first-page":"817","DOI":"10.1016\/S0140-6736(08)61171-X","article-title":"Heart rate as a prognostic risk factor in patients with coronary artery disease and left-ventricular systolic dysfunction (BEAUTIFUL): A subgroup analysis of a randomised controlled trial","volume":"372","author":"Fox","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0275","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa1406430","article-title":"Ivabradine in stable coronary artery disease without clinical heart failure","volume":"371","author":"Fox","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0280","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1161\/CIRCULATIONAHA.110.983023","article-title":"Deletion of cardiomyocyte mineralocorticoid receptor ameliorates adverse remodeling after myocardial infarction","volume":"123","author":"Fraccarollo","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0285","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1124\/pr.110.002907","article-title":"cGMP-dependent protein kinases and cGMP phosphodiesterases in nitric oxide and cGMP action","volume":"62","author":"Francis","year":"2010","journal-title":"Pharmacol Rev"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0290","doi-asserted-by":"crossref","first-page":"448","DOI":"10.1161\/01.CIR.99.3.448","article-title":"Magnetic resonance imaging and invasive evaluation of development of heart failure in transgenic mice with myocardial expression of tumor necrosis factor-alpha","volume":"99","author":"Franco","year":"1999","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0295","doi-asserted-by":"crossref","first-page":"2251","DOI":"10.1001\/jama.2015.15734","article-title":"Effect of vericiguat, a soluble guanylate cyclase stimulator, on natriuretic peptide levels in patients with worsening chronic heart failure and reduced ejection fraction: The SOCRATES-REDUCED Randomized Trial","volume":"314","author":"Gheorghiade","year":"2015","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0300","doi-asserted-by":"crossref","first-page":"68","DOI":"10.1016\/j.yjmcc.2015.09.017","article-title":"Harnessing the microRNA pathway for cardiac regeneration","volume":"89","author":"Giacca","year":"2015","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0305","doi-asserted-by":"crossref","first-page":"5288","DOI":"10.1038\/ncomms6288","article-title":"Dynamic DNA methylation orchestrates cardiomyocyte development, maturation and disease","volume":"5","author":"Gilsbach","year":"2014","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0310","doi-asserted-by":"crossref","first-page":"1255555","DOI":"10.1126\/science.1255555","article-title":"Neurodegeneration. Alzheimer's and Parkinson's diseases: The prion concept in relation to assembled Abeta, tau, and alpha-synuclein","volume":"349","author":"Goedert","year":"2015","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0315","doi-asserted-by":"crossref","first-page":"772","DOI":"10.1016\/S0140-6736(03)14284-5","article-title":"Effects of candesartan in patients with chronic heart failure and reduced left-ventricular systolic function intolerant to angiotensin-converting-enzyme inhibitors: The CHARM-Alternative trial","volume":"362","author":"Granger","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0320","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1016\/j.jchf.2014.07.009","article-title":"Safety and tolerability of omecamtiv mecarbil during exercise in patients with ischemic cardiomyopathy and angina","volume":"3","author":"Greenberg","year":"2015","journal-title":"JACC Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0325","doi-asserted-by":"crossref","first-page":"1178","DOI":"10.1016\/S0140-6736(16)00082-9","article-title":"Calcium upregulation by percutaneous administration of gene therapy in patients with cardiac disease (CUPID 2): A randomised, multinational, double-blind, placebo-controlled, phase 2b trial","volume":"387","author":"Greenberg","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0330","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1016\/j.chembiol.2012.04.014","article-title":"Nuclear shuttling precedes dimerization in mineralocorticoid receptor signaling","volume":"19","author":"Grossmann","year":"2012","journal-title":"Chem Biol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0335","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1177\/0091270009343932","article-title":"Pharmacokinetics and pharmacodynamics of LCZ696, a novel dual-acting angiotensin receptor-neprilysin inhibitor (ARNi)","volume":"50","author":"Gu","year":"2010","journal-title":"J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0340","doi-asserted-by":"crossref","first-page":"6753","DOI":"10.1073\/pnas.86.17.6753","article-title":"Interleukin 1 and tumor necrosis factor inhibit cardiac myocyte beta-adrenergic responsiveness","volume":"86","author":"Gulick","year":"1989","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0345","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1002\/emmm.201201553","article-title":"Alterations in cardiac DNA methylation in human dilated cardiomyopathy","volume":"5","author":"Haas","year":"2013","journal-title":"EMBO Mol Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0350","doi-asserted-by":"crossref","first-page":"1859","DOI":"10.1016\/0022-2828(95)90009-8","article-title":"Cardiac troponin C as a target protein for a novel calcium sensitizing drug, levosimendan","volume":"27","author":"Haikala","year":"1995","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0355","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1161\/CIRCRESAHA.114.301798","article-title":"MicroRNA regulation and cardiac calcium signaling: Role in cardiac disease and therapeutic potential","volume":"114","author":"Harada","year":"2014","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0360","doi-asserted-by":"crossref","first-page":"868","DOI":"10.1161\/hc0702.104164","article-title":"Fluvastatin, a 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibitor, attenuates left ventricular remodeling and failure after experimental myocardial infarction","volume":"105","author":"Hayashidani","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0365","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1016\/S0140-6736(14)60107-0","article-title":"Cardiovascular remodelling in coronary artery disease and heart failure","volume":"383","author":"Heusch","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0370","doi-asserted-by":"crossref","first-page":"1359","DOI":"10.1172\/JCI61084","article-title":"HDAC4 controls histone methylation in response to elevated cardiac load","volume":"123","author":"Hohl","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0375","doi-asserted-by":"crossref","first-page":"1399","DOI":"10.1172\/JCI17061","article-title":"Pressure-independent cardiac hypertrophy in mice with cardiomyocyte-restricted inactivation of the atrial natriuretic peptide receptor guanylyl cyclase-A","volume":"111","author":"Holtwick","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0380","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/77399","article-title":"Identification of the major Abeta1-42-degrading catabolic pathway in brain parenchyma: Suppression leads to biochemical and pathological deposition","volume":"6","author":"Iwata","year":"2000","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0385","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1126\/science.1059946","article-title":"Metabolic regulation of brain Abeta by neprilysin","volume":"292","author":"Iwata","year":"2001","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0390","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1056\/NEJMoa1209026","article-title":"Treatment of HCV infection by targeting microRNA","volume":"368","author":"Janssen","year":"2013","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0395","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1161\/CIRCULATIONAHA.111.022889","article-title":"Calcium Upregulation by Percutaneous Administration of Gene Therapy in Cardiac Disease (CUPID): A phase 2 trial of intracoronary gene therapy of sarcoplasmic reticulum Ca2+-ATPase in patients with advanced heart failure","volume":"124","author":"Jessup","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0400","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nrg3965","article-title":"Towards a molecular understanding of microRNA-mediated gene silencing","volume":"16","author":"Jonas","year":"2015","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0405","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1038\/nrg3230","article-title":"Functions of DNA methylation: Islands, start sites, gene bodies and beyond","volume":"13","author":"Jones","year":"2012","journal-title":"Nat Rev Genet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0410","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/hc3501.096063","article-title":"Anti-tumor necrosis factor-alpha antibody limits heart failure in a transgenic model","volume":"104","author":"Kadokami","year":"2001","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0415","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1124\/mol.114.096974","article-title":"Histone deacetylase inhibition attenuates cardiac hypertrophy and fibrosis through acetylation of mineralocorticoid receptor in spontaneously hypertensive rats","volume":"87","author":"Kang","year":"2015","journal-title":"Mol Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0420","doi-asserted-by":"crossref","first-page":"4178","DOI":"10.1016\/j.ijcard.2013.07.111","article-title":"Histone deacetylase inhibition improved cardiac functions with direct antifibrotic activity in heart failure","volume":"168","author":"Kao","year":"2013","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0425","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1038\/nm0109-24","article-title":"Rescuing a failing heart: Putting on the squeeze","volume":"15","author":"Kass","year":"2009","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0430","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1016\/j.jacc.2007.12.014","article-title":"Reversal of cardiac dysfunction after long-term expression of SERCA2a by gene transfer in a pre-clinical model of heart failure","volume":"51","author":"Kawase","year":"2008","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0435","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1016\/j.yjmcc.2009.08.022","article-title":"Kruppel-like factor 4 mediates histone deacetylase inhibitor-induced prevention of cardiac hypertrophy","volume":"47","author":"Kee","year":"2009","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0440","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.ahj.2015.03.018","article-title":"PDE 5 inhibition with udenafil improves left ventricular systolic\/diastolic functions and exercise capacity in patients with chronic heart failure with reduced ejection fraction: A 12-week, randomized, double-blind, placebo-controlled trial","volume":"169","author":"Kim","year":"2015","journal-title":"Am Heart J"},{"issue":"Suppl. H","key":"10.1016\/j.pharmthera.2016.07.004_bb0445","first-page":"H64","article-title":"Heart rate as a therapeutic target in heart failure","volume":"1999","author":"Kjekshus","year":"1999","journal-title":"Eur Heart J Suppl"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0450","doi-asserted-by":"crossref","first-page":"2248","DOI":"10.1056\/NEJMoa0706201","article-title":"Rosuvastatin in older patients with systolic heart failure","volume":"357","author":"Kjekshus","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0455","doi-asserted-by":"crossref","first-page":"1350","DOI":"10.1126\/science.7761854","article-title":"Cardiac function in mice overexpressing the beta-adrenergic receptor kinase or a beta ARK inhibitor","volume":"268","author":"Koch","year":"1995","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0460","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1097\/FJC.0000000000000091","article-title":"Finerenone, a novel selective nonsteroidal mineralocorticoid receptor antagonist protects from rat cardiorenal injury","volume":"64","author":"Kolkhof","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0465","doi-asserted-by":"crossref","first-page":"2579","DOI":"10.1161\/CIRCULATIONAHA.106.625467","article-title":"Suppression of class I and II histone deacetylases blunts pressure-overload cardiac hypertrophy","volume":"113","author":"Kong","year":"2006","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0470","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1152\/physrev.00022.2015","article-title":"Molecular physiology of membrane guanylyl cyclase receptors","volume":"96","author":"Kuhn","year":"2016","journal-title":"Physiol Rev"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0475","doi-asserted-by":"crossref","first-page":"676","DOI":"10.1161\/CIRCRESAHA.113.300226","article-title":"Non-coding RNAs in cardiac remodeling and heart failure","volume":"113","author":"Kumarswamy","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0480","doi-asserted-by":"crossref","first-page":"1409","DOI":"10.1093\/ajh\/hpv015","article-title":"LCZ696, angiotensin II receptor-neprilysin inhibitor, ameliorates high-salt-induced hypertension and cardiovascular injury more than valsartan alone","volume":"28","author":"Kusaka","year":"2015","journal-title":"Am J Hypertens"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0485","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1016\/j.ijcard.2015.05.127","article-title":"Safety profile of mineralocorticoid receptor antagonists: Spironolactone and eplerenone","volume":"200","author":"Lainscak","year":"2015","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0490","doi-asserted-by":"crossref","first-page":"1933","DOI":"10.1161\/01.CIR.0000143232.67642.7A","article-title":"Statin-induced improvement of endothelial progenitor cell mobilization, myocardial neovascularization, left ventricular function, and survival after experimental myocardial infarction requires endothelial nitric oxide synthase","volume":"110","author":"Landmesser","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0495","doi-asserted-by":"crossref","first-page":"878","DOI":"10.1111\/bcp.12861","article-title":"The effect of LCZ696 (sacubitril\/valsartan) on amyloid-beta concentrations in cerebrospinal fluid in healthy subjects","volume":"81","author":"Langenickel","year":"2016","journal-title":"Br J Clin Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0500","doi-asserted-by":"crossref","first-page":"6656","DOI":"10.1074\/jbc.M113.519256","article-title":"The mineralocorticoid receptor promotes fibrotic remodeling in atrial fibrillation","volume":"289","author":"Lavall","year":"2014","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0505","doi-asserted-by":"crossref","first-page":"936","DOI":"10.1038\/ki.2009.9","article-title":"Aldosterone antagonism or synthase inhibition reduces end-organ damage induced by treatment with angiotensin and high salt","volume":"75","author":"Lea","year":"2009","journal-title":"Kidney Int"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0510","doi-asserted-by":"crossref","first-page":"1004","DOI":"10.1161\/CIRCRESAHA.113.301071","article-title":"Histone deacetylase inhibition attenuates transcriptional activity of mineralocorticoid receptor through its acetylation and prevents development of hypertension","volume":"112","author":"Lee","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0515","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1161\/CIRCULATIONAHA.106.626226","article-title":"Sildenafil improves exercise hemodynamics and oxygen uptake in patients with systolic heart failure","volume":"115","author":"Lewis","year":"2007","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0520","doi-asserted-by":"crossref","first-page":"e110950","DOI":"10.1371\/journal.pone.0110950","article-title":"Myeloid mineralocorticoid receptor deficiency inhibits aortic constriction-induced cardiac hypertrophy in mice","volume":"9","author":"Li","year":"2014","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0525","doi-asserted-by":"crossref","first-page":"1325","DOI":"10.1002\/jnr.23564","article-title":"Neprilysin gene transfer: A promising therapeutic approach for Alzheimer's disease","volume":"93","author":"Li","year":"2015","journal-title":"J Neurosci Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0530","doi-asserted-by":"crossref","first-page":"H1773","DOI":"10.1152\/ajpheart.00411.2006","article-title":"Percutaneous intracoronary delivery of SERCA gene increases myocardial function: A tissue Doppler imaging echocardiographic study","volume":"291","author":"Logeart","year":"2006","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0535","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1161\/HYPERTENSIONAHA.116.07418","article-title":"Vascular mineralocorticoid receptors: Linking risk factors, hypertension, and heart disease","volume":"68","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0540","doi-asserted-by":"crossref","first-page":"746","DOI":"10.1161\/HYPERTENSIONAHA.110.163287","article-title":"Ablation of mineralocorticoid receptors in myocytes but not in fibroblasts preserves cardiac function","volume":"57","author":"Lother","year":"2011","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0545","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1146\/annurev-pharmtox-010814-124302","article-title":"Mineralocorticoids in the heart and vasculature: New insights for old hormones","volume":"55","author":"Lother","year":"2015","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0550","doi-asserted-by":"crossref","first-page":"130","DOI":"10.1161\/HYPERTENSIONAHA.115.06530","article-title":"Deoxycorticosterone acetate\/salt-induced cardiac but not renal injury is mediated by endothelial mineralocorticoid receptors independently from blood pressure","volume":"67","author":"Lother","year":"2016","journal-title":"Hypertension"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0555","doi-asserted-by":"crossref","first-page":"1474","DOI":"10.1161\/CIRCULATIONAHA.109.906818","article-title":"Oxidative stress regulates left ventricular PDE5 expression in the failing heart","volume":"121","author":"Lu","year":"2010","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0560","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1161\/CIRCRESAHA.113.301651","article-title":"Mechanisms of altered Ca(2)(+) handling in heart failure","volume":"113","author":"Luo","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0565","doi-asserted-by":"crossref","first-page":"e0145666","DOI":"10.1371\/journal.pone.0145666","article-title":"Suppression of rapidly progressive mouse glomerulonephritis with the non-steroidal mineralocorticoid receptor antagonist BR-4628","volume":"10","author":"Ma","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0570","doi-asserted-by":"crossref","first-page":"1414","DOI":"10.1016\/S0735-1097(02)02304-5","article-title":"Effects of valsartan on morbidity and mortality in patients with heart failure not receiving angiotensin-converting enzyme inhibitors","volume":"40","author":"Maggioni","year":"2002","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0575","doi-asserted-by":"crossref","first-page":"1439","DOI":"10.1126\/science.1200113","article-title":"Cardiac myosin activation: A potential therapeutic approach for systolic heart failure","volume":"331","author":"Malik","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0580","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1161\/CIRCRESAHA.116.302317","article-title":"Innate immunity and the failing heart: The cytokine hypothesis revisited","volume":"116","author":"Mann","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0585","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1161\/01.CIR.0000124490.27666.B2","article-title":"Targeted anticytokine therapy in patients with chronic heart failure: Results of the Randomized Etanercept Worldwide Evaluation (RENEWAL)","volume":"109","author":"Mann","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0590","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1159\/000073933","article-title":"A single intravenous dose of ivabradine, a novel I(f) inhibitor, lowers heart rate but does not depress left ventricular function in patients with left ventricular dysfunction","volume":"100","author":"Manz","year":"2003","journal-title":"Cardiology"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0595","doi-asserted-by":"crossref","first-page":"46","DOI":"10.1172\/JCI62834","article-title":"Calcium cycling proteins and heart failure: Mechanisms and therapeutics","volume":"123","author":"Marks","year":"2013","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0600","doi-asserted-by":"crossref","first-page":"790","DOI":"10.1093\/nar\/gkt896","article-title":"The primary microRNA-208b interacts with polycomb-group protein, Ezh2, to regulate gene expression in the heart","volume":"42","author":"Mathiyalagan","year":"2014","journal-title":"Nucleic Acids Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0605","doi-asserted-by":"crossref","first-page":"622","DOI":"10.1161\/CIRCRESAHA.115.306721","article-title":"Adrenergic repression of the epigenetic reader MeCP2 facilitates cardiac adaptation in chronic heart failure","volume":"117","author":"Mayer","year":"2015","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0610","doi-asserted-by":"crossref","first-page":"303","DOI":"10.1146\/annurev-pharmtox-010611-134712","article-title":"Therapeutic potential for HDAC inhibitors in the heart","volume":"52","author":"McKinsey","year":"2012","journal-title":"Annu Rev Pharmacol Toxicol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0615","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1093\/eurheartj\/ehv190","article-title":"It is BEAUTIFUL we should be concerned about, not SIGNIFY: Is ivabradine less effective in ischaemic compared with non-ischaemic LVSD?","volume":"36","author":"McMurray","year":"2015","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0620","doi-asserted-by":"crossref","first-page":"242","DOI":"10.1002\/ejhf.250","article-title":"Neprilysin inhibition to treat heart failure: A tale of science, serendipity, and second chances","volume":"17","author":"McMurray","year":"2015","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0625","doi-asserted-by":"crossref","first-page":"993","DOI":"10.1056\/NEJMoa1409077","article-title":"Angiotensin-neprilysin inhibition versus enalapril in heart failure","volume":"371","author":"McMurray","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0630","doi-asserted-by":"crossref","first-page":"1883","DOI":"10.1001\/jama.297.17.1883","article-title":"Levosimendan vs dobutamine for patients with acute decompensated heart failure: The SURVIVE Randomized Trial","volume":"297","author":"Mebazaa","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0635","doi-asserted-by":"crossref","first-page":"2001","DOI":"10.1016\/S0140-6736(99)04440-2","article-title":"Effect of metoprolol CR\/XL in chronic heart failure: Metoprolol CR\/XL Randomised Intervention Trial in Congestive Heart Failure (MERIT-HF)","volume":"353","author":"MERIT-HF","year":"1999","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0640","doi-asserted-by":"crossref","first-page":"793","DOI":"10.1073\/pnas.97.2.793","article-title":"Adenoviral gene transfer of SERCA2a improves left-ventricular function in aortic-banded rats in transition to heart failure","volume":"97","author":"Miyamoto","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0645","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1146\/annurev.physiol.63.1.391","article-title":"Cytoplasmic signaling pathways that regulate cardiac hypertrophy","volume":"63","author":"Molkentin","year":"2001","journal-title":"Annu Rev Physiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0650","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1161\/CIRCULATIONAHA.111.030932","article-title":"Therapeutic inhibition of miR-208a improves cardiac function and survival during heart failure","volume":"124","author":"Montgomery","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0655","doi-asserted-by":"crossref","first-page":"2411","DOI":"10.1161\/CIRCULATIONAHA.111.040071","article-title":"Distinct epigenomic features in end-stage failing human hearts","volume":"124","author":"Movassagh","year":"2011","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0660","doi-asserted-by":"crossref","first-page":"1674","DOI":"10.1161\/01.CIR.0000118464.48959.1C","article-title":"Long-term heart rate reduction induced by the selective I(f) current inhibitor ivabradine improves left ventricular function and intrinsic myocardial structure in congestive heart failure","volume":"109","author":"Mulder","year":"2004","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0665","doi-asserted-by":"crossref","first-page":"2171","DOI":"10.1093\/eurheartj\/ehn277","article-title":"Aldosterone synthase inhibition improves cardiovascular function and structure in rats with heart failure: A comparison with spironolactone","volume":"29","author":"Mulder","year":"2008","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0670","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1007\/s00441-014-1887-8","article-title":"Epigenetics in cardiac development, function, and disease","volume":"356","author":"Nuhrenberg","year":"2014","journal-title":"Cell Tissue Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0675","doi-asserted-by":"crossref","first-page":"217","DOI":"10.1016\/j.preteyeres.2011.02.004","article-title":"Parallel findings in age-related macular degeneration and Alzheimer's disease","volume":"30","author":"Ohno-Matsui","year":"2011","journal-title":"Prog Retin Eye Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0680","doi-asserted-by":"crossref","first-page":"e0115547","DOI":"10.1371\/journal.pone.0115547","article-title":"The inotropic effect of the active metabolite of levosimendan, OR-1896, is mediated through inhibition of PDE3 in rat ventricular myocardium","volume":"10","author":"Orstavik","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0685","doi-asserted-by":"crossref","first-page":"2194","DOI":"10.1161\/01.CIR.0000035653.72855.BF","article-title":"Effect of carvedilol on the morbidity of patients with severe chronic heart failure: Results of the carvedilol prospective randomized cumulative survival (COPERNICUS) study","volume":"106","author":"Packer","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0690","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1161\/CIRCULATIONAHA.114.013748","article-title":"Angiotensin receptor neprilysin inhibition compared with enalapril on the risk of clinical progression in surviving patients with heart failure","volume":"131","author":"Packer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0695","doi-asserted-by":"crossref","first-page":"e002137","DOI":"10.1161\/JAHA.115.002137","article-title":"Effect of mineralocorticoid receptor antagonists on cardiac structure and function in patients with diastolic dysfunction and heart failure with preserved ejection fraction: A meta-analysis and systematic review","volume":"4","author":"Pandey","year":"2015","journal-title":"J Am Heart Assoc"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0700","doi-asserted-by":"crossref","first-page":"H777","DOI":"10.1152\/ajpheart.00117.2005","article-title":"Cardiac-specific attenuation of natriuretic peptide A receptor activity accentuates adverse cardiac remodeling and mortality in response to pressure overload","volume":"289","author":"Patel","year":"2005","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0705","doi-asserted-by":"crossref","first-page":"3912","DOI":"10.1172\/JCI43604","article-title":"Stress-dependent cardiac remodeling occurs in the absence of microRNA-21 in mice","volume":"120","author":"Patrick","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0710","doi-asserted-by":"crossref","first-page":"12925","DOI":"10.1073\/pnas.1414364111","article-title":"Roles of cGMP-dependent protein kinase I (cGKI) and PDE5 in the regulation of Ang II-induced cardiac hypertrophy and fibrosis","volume":"111","author":"Patrucco","year":"2014","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0715","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.jacc.2013.02.092","article-title":"A novel paradigm for heart failure with preserved ejection fraction: Comorbidities drive myocardial dysfunction and remodeling through coronary microvascular endothelial inflammation","volume":"62","author":"Paulus","year":"2013","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0720","doi-asserted-by":"crossref","first-page":"1893","DOI":"10.1056\/NEJMoa032292","article-title":"Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both","volume":"349","author":"Pfeffer","year":"2003","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0725","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1161\/CIRCULATIONAHA.114.013255","article-title":"Regional variation in patients and outcomes in the Treatment of Preserved Cardiac Function Heart Failure With an Aldosterone Antagonist (TOPCAT) trial","volume":"131","author":"Pfeffer","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0730","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1002\/ejhf.135","article-title":"Rationale and design of the SOluble guanylate Cyclase stimulatoR in heArT failurE Studies (SOCRATES)","volume":"16","author":"Pieske","year":"2014","journal-title":"Eur J Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0735","doi-asserted-by":"crossref","first-page":"709","DOI":"10.1056\/NEJM199909023411001","article-title":"The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized Aldactone Evaluation Study Investigators","volume":"341","author":"Pitt","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0740","doi-asserted-by":"crossref","first-page":"2453","DOI":"10.1093\/eurheartj\/eht187","article-title":"Safety and tolerability of the novel non-steroidal mineralocorticoid receptor antagonist BAY 94-8862 in patients with chronic heart failure and mild or moderate chronic kidney disease: A randomized, double-blind trial","volume":"34","author":"Pitt","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0745","doi-asserted-by":"crossref","first-page":"1383","DOI":"10.1056\/NEJMoa1313731","article-title":"Spironolactone for heart failure with preserved ejection fraction","volume":"370","author":"Pitt","year":"2014","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0750","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1111\/nyas.12393","article-title":"The journey from stem cell to macrophage","volume":"1319","author":"Pittet","year":"2014","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0755","doi-asserted-by":"crossref","first-page":"92ra64","DOI":"10.1126\/scitranslmed.3002097","article-title":"Cardiac AAV9-S100A1 gene therapy rescues post-ischemic heart failure in a preclinical large animal model","volume":"3","author":"Pleger","year":"2011","journal-title":"Sci Transl Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0760","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1161\/CIRCRESAHA.113.300269","article-title":"Heart failure gene therapy: The path to clinical practice","volume":"113","author":"Pleger","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0765","doi-asserted-by":"crossref","first-page":"408","DOI":"10.1161\/CIRCULATIONAHA.108.822072","article-title":"Ventricular phosphodiesterase-5 expression is increased in patients with advanced heart failure and contributes to adverse ventricular remodeling after myocardial infarction in mice","volume":"119","author":"Pokreisz","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0770","doi-asserted-by":"crossref","first-page":"2129","DOI":"10.1093\/eurheartj\/ehw128","volume":"37","author":"Ponikowski","year":"2016","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0775","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.ijcard.2016.04.098","article-title":"Soluble guanylate cyclase stimulator riociguat and phosphodiesterase 5 inhibitor sildenafil ameliorate pulmonary hypertension due to left heart disease in mice","volume":"216","author":"Pradhan","year":"2016","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0780","doi-asserted-by":"crossref","first-page":"413","DOI":"10.1161\/CIRCRESAHA.107.168336","article-title":"G protein-coupled receptor kinase 2 ablation in cardiac myocytes before or after myocardial infarction prevents heart failure","volume":"103","author":"Raake","year":"2008","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0785","doi-asserted-by":"crossref","first-page":"1437","DOI":"10.1093\/eurheartj\/ehr447","article-title":"AAV6.betaARKct cardiac gene therapy ameliorates cardiac function and normalizes the catecholaminergic axis in a clinically relevant large animal heart failure model","volume":"34","author":"Raake","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0790","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/S0009-9236(98)90153-9","article-title":"Pharmacokinetic\u2013pharmacodynamic modeling of the effects of ivabradine, a direct sinus node inhibitor, on heart rate in healthy volunteers","volume":"64","author":"Ragueneau","year":"1998","journal-title":"Clin Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0795","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1001\/jama.2013.2024","article-title":"Effect of phosphodiesterase-5 inhibition on exercise capacity and clinical status in heart failure with preserved ejection fraction: A randomized clinical trial","volume":"309","author":"Redfield","year":"2013","journal-title":"JAMA"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0800","doi-asserted-by":"crossref","first-page":"2839","DOI":"10.1093\/eurheartj\/ehs218","article-title":"Heart rate reduction by If-inhibition improves vascular stiffness and left ventricular systolic and diastolic function in a mouse model of heart failure with preserved ejection fraction","volume":"34","author":"Reil","year":"2013","journal-title":"Eur Heart J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0805","doi-asserted-by":"crossref","first-page":"1094","DOI":"10.1161\/CIRCHEARTFAILURE.114.001781","article-title":"HDACs regulate miR-133a expression in pressure overload-induced cardiac fibrosis","volume":"8","author":"Renaud","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0810","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1016\/j.yjmcc.2010.08.014","article-title":"GRK2 as a novel gene therapy target in heart failure","volume":"50","author":"Rengo","year":"2011","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0815","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1016\/j.pharmthera.2009.08.001","article-title":"Exploiting cGMP-based therapies for the prevention of left ventricular hypertrophy: NO* and beyond","volume":"124","author":"Ritchie","year":"2009","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0820","doi-asserted-by":"crossref","first-page":"18180","DOI":"10.1074\/jbc.273.29.18180","article-title":"Control of myocardial contractile function by the level of beta-adrenergic receptor kinase 1 in gene-targeted mice","volume":"273","author":"Rockman","year":"1998","journal-title":"J Biol Chem"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0825","doi-asserted-by":"crossref","first-page":"646","DOI":"10.1161\/CIRCRESAHA.113.300268","article-title":"Epidemiology of heart failure","volume":"113","author":"Roger","year":"2013","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0830","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1016\/S0140-6736(09)61966-8","article-title":"Blood-pressure reduction with LCZ696, a novel dual-acting inhibitor of the angiotensin II receptor and neprilysin: A randomised, double-blind, placebo-controlled, active comparator study","volume":"375","author":"Ruilope","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0835","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1038\/nm.3972","article-title":"Cardiac RKIP induces a beneficial beta-adrenoceptor-dependent positive inotropy","volume":"21","author":"Schmid","year":"2015","journal-title":"Nat Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0840","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1038\/nature14192","article-title":"Function and information content of DNA methylation","volume":"517","author":"Schubeler","year":"2015","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0845","doi-asserted-by":"crossref","first-page":"968","DOI":"10.1096\/fj.10-173286","article-title":"Mineralocorticoid receptor-mediated DNA damage in kidneys of DOCA-salt hypertensive rats","volume":"25","author":"Schupp","year":"2011","journal-title":"FASEB J"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0850","doi-asserted-by":"crossref","first-page":"1387","DOI":"10.1016\/S0140-6736(12)61227-6","article-title":"The angiotensin receptor neprilysin inhibitor LCZ696 in heart failure with preserved ejection fraction: A phase 2 double-blind randomised controlled trial","volume":"380","author":"Solomon","year":"2012","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0855","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1056\/NEJM199108013250501","article-title":"Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure. The SOLVD Investigators","volume":"325","author":"SOLVD","year":"1991","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0860","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1056\/NEJM199209033271003","article-title":"Effect of enalapril on mortality and the development of heart failure in asymptomatic patients with reduced left ventricular ejection fractions. The SOLVD Investigattors","volume":"327","author":"SOLVD","year":"1992","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0865","doi-asserted-by":"crossref","first-page":"175","DOI":"10.1016\/j.yjmcc.2013.07.017","article-title":"BET acetyl-lysine binding proteins control pathological cardiac hypertrophy","volume":"63","author":"Spiltoir","year":"2013","journal-title":"J Mol Cell Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0870","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1007\/s00395-015-0528-z","article-title":"DNA methylation in an engineered heart tissue model of cardiac hypertrophy: Common signatures and effects of DNA methylation inhibitors","volume":"111","author":"Stenzig","year":"2016","journal-title":"Basic Res Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0875","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1161\/CIRCULATIONAHA.108.783852","article-title":"Long-term cardiac-targeted RNA interference for the treatment of heart failure restores cardiac function and reduces pathological hypertrophy","volume":"119","author":"Suckau","year":"2009","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0880","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/S0140-6736(10)61198-1","article-title":"Ivabradine and outcomes in chronic heart failure (SHIFT): A randomised placebo-controlled study","volume":"376","author":"Swedberg","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0885","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1016\/j.jacc.2012.01.020","article-title":"Effects on outcomes of heart rate reduction by ivabradine in patients with congestive heart failure: Is there an influence of beta-blocker dose? Findings from the SHIFT (Systolic Heart failure treatment with the I(f) inhibitor ivabradine Trial) study","volume":"59","author":"Swedberg","year":"2012","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0890","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1126\/science.1230719","article-title":"Leukocyte behavior in atherosclerosis, myocardial infarction, and heart failure","volume":"339","author":"Swirski","year":"2013","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0895","doi-asserted-by":"crossref","first-page":"1231","DOI":"10.1016\/S0140-6736(08)61240-4","article-title":"Effect of rosuvastatin in patients with chronic heart failure (the GISSI-HF trial): A randomised, double-blind, placebo-controlled trial","volume":"372","author":"Tavazzi","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0900","doi-asserted-by":"crossref","first-page":"667","DOI":"10.1016\/S0140-6736(11)61219-1","article-title":"Dose-dependent augmentation of cardiac systolic function with the selective cardiac myosin activator, omecamtiv mecarbil: A first-in-man study","volume":"378","author":"Teerlink","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0905","first-page":"2267","article-title":"Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure (COSMIC-HF): Final results from a double-blind, randomized, placebo-controlled, multicenter study","volume":"132","author":"Teerlink","year":"2015","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0910","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1016\/j.jacc.2016.01.031","article-title":"Acute Treatment with Omecamtiv Mecarbil to Increase Contractility in Acute Heart Failure: The ATOMIC-AHF Study","volume":"67","author":"Teerlink","year":"2016","journal-title":"J Am Coll Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0915","doi-asserted-by":"crossref","first-page":"1830","DOI":"10.1021\/cb3003013","article-title":"Paroxetine is a direct inhibitor of G protein-coupled receptor kinase 2 and increases myocardial contractility","volume":"7","author":"Thal","year":"2012","journal-title":"ACS Chem Biol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0920","doi-asserted-by":"crossref","first-page":"980","DOI":"10.1038\/nature07511","article-title":"MicroRNA-21 contributes to myocardial disease by stimulating MAP kinase signalling in fibroblasts","volume":"456","author":"Thum","year":"2008","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0925","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1172\/JCI45938","article-title":"Comparison of different miR-21 inhibitor chemistries in a cardiac disease model","volume":"121","author":"Thum","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0930","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1097\/FJC.0000000000000106","article-title":"Interleukin-1beta blockade improves left ventricular systolic\/diastolic function and restores contractility reserve in severe ischemic cardiomyopathy in the mouse","volume":"64","author":"Toldo","year":"2014","journal-title":"J Cardiovasc Pharmacol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0935","doi-asserted-by":"crossref","first-page":"H1025","DOI":"10.1152\/ajpheart.00795.2013","article-title":"Interleukin-18 mediates interleukin-1-induced cardiac dysfunction","volume":"306","author":"Toldo","year":"2014","journal-title":"Am J Physiol Heart Circ Physiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0940","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1038\/ncomms2090","article-title":"The miRNA-212\/132 family regulates both cardiac hypertrophy and cardiomyocyte autophagy","volume":"3","author":"Ucar","year":"2012","journal-title":"Nat Commun"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0945","doi-asserted-by":"crossref","first-page":"3350","DOI":"10.1172\/JCI41080","article-title":"Myeloid mineralocorticoid receptor controls macrophage polarization and cardiovascular hypertrophy and remodeling in mice","volume":"120","author":"Usher","year":"2010","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0950","doi-asserted-by":"crossref","first-page":"575","DOI":"10.1126\/science.1139089","article-title":"Control of stress-dependent cardiac growth and gene expression by a microRNA","volume":"316","author":"van Rooij","year":"2007","journal-title":"Science"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0955","doi-asserted-by":"crossref","first-page":"e33438","DOI":"10.1371\/journal.pone.0033438","article-title":"Enhanced interleukin-1 activity contributes to exercise intolerance in patients with systolic heart failure","volume":"7","author":"Van Tassell","year":"2012","journal-title":"PLoS One"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0960","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1016\/j.amjcard.2013.08.047","article-title":"Effects of interleukin-1 blockade with anakinra on aerobic exercise capacity in patients with heart failure and preserved ejection fraction (from the D-HART pilot study)","volume":"113","author":"Van Tassell","year":"2014","journal-title":"Am J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0965","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1038\/nrm3941","article-title":"Histone exchange, chromatin structure and the regulation of transcription","volume":"16","author":"Venkatesh","year":"2015","journal-title":"Nat Rev Mol Cell Biol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0970","doi-asserted-by":"crossref","first-page":"218","DOI":"10.1016\/j.ijcard.2011.06.098","article-title":"Effect of Carvedilol, Ivabradine or their combination on exercise capacity in patients with Heart Failure (the CARVIVA HF trial)","volume":"151","author":"Volterrani","year":"2011","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0975","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1016\/j.pharmthera.2014.05.002","article-title":"Current role of neprilysin inhibitors in hypertension and heart failure","volume":"144","author":"von Lueder","year":"2014","journal-title":"Pharmacol Ther"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0980","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1161\/CIRCHEARTFAILURE.114.001785","article-title":"Angiotensin receptor neprilysin inhibitor LCZ696 attenuates cardiac remodeling and dysfunction after myocardial infarction by reducing cardiac fibrosis and hypertrophy","volume":"8","author":"von Lueder","year":"2015","journal-title":"Circ Heart Fail"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0985","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1038\/nature13073","article-title":"Inhibition of miR-25 improves cardiac contractility in the failing heart","volume":"508","author":"Wahlquist","year":"2014","journal-title":"Nature"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0990","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1093\/cvr\/cvv015","article-title":"Epigenetic balance of aberrant Rasal1 promoter methylation and hydroxymethylation regulates cardiac fibrosis","volume":"105","author":"Xu","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb0995","doi-asserted-by":"crossref","first-page":"489","DOI":"10.1161\/01.RES.0000258451.44949.d7","article-title":"Regulation of phosphodiesterase 3 and inducible cAMP early repressor in the heart","volume":"100","author":"Yan","year":"2007","journal-title":"Circ Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb1000","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1093\/cvr\/cvu254","article-title":"miR-21-3p regulates cardiac hypertrophic response by targeting histone deacetylase-8","volume":"105","author":"Yan","year":"2015","journal-title":"Cardiovasc Res"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb1005","author":"Yancy","year":"2016","journal-title":"Circulation"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb1010","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1009492","article-title":"Eplerenone in patients with systolic heart failure and mild symptoms","volume":"364","author":"Zannad","year":"2011","journal-title":"N Engl J Med"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb1015","doi-asserted-by":"crossref","first-page":"2447","DOI":"10.1172\/JCI46277","article-title":"The histone trimethyllysine demethylase JMJD2A promotes cardiac hypertrophy in response to hypertrophic stimuli in mice","volume":"121","author":"Zhang","year":"2011","journal-title":"J Clin Invest"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb1020","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1016\/j.ijcard.2014.01.102","article-title":"PDE5 inhibitor sildenafil in the treatment of heart failure: A meta-analysis of randomized controlled trials","volume":"172","author":"Zhuang","year":"2014","journal-title":"Int J Cardiol"},{"key":"10.1016\/j.pharmthera.2016.07.004_bb1025","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1161\/CIRCRESAHA.113.302421","article-title":"Long-term effects of AAV1\/SERCA2a gene transfer in patients with severe heart failure: Analysis of recurrent cardiovascular events and mortality","volume":"114","author":"Zsebo","year":"2014","journal-title":"Circ Res"}],"container-title":["Pharmacology & Therapeutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301243?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0163725816301243?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,5,17]],"date-time":"2020-05-17T02:05:09Z","timestamp":1589681109000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0163725816301243"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,10]]},"references-count":205,"alternative-id":["S0163725816301243"],"URL":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.07.004","relation":{},"ISSN":["0163-7258"],"issn-type":[{"value":"0163-7258","type":"print"}],"subject":[],"published":{"date-parts":[[2016,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Pharmacology of heart failure: From basic science to novel therapies","name":"articletitle","label":"Article Title"},{"value":"Pharmacology & Therapeutics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.pharmthera.2016.07.004","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2016 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}